ClinicalTrials.gg
TerminatedNCT00423150Updated Jun 8, 2017Results posted

Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)

A Phase 2 interventional study of Temozolomide in Colorectal Neoplasm, Head and Neck Neoplasm and Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Colorectal Neoplasms by Merck & Co., Inc — 1 open to participants now, 3 under way, 1 of them phase 3. Colorectal Neoplasms · Merck & Co., Inc.

Enrollment
15th of 24
86 · median 106
Started
2007
with 2 others
Phase 2
9 of 25
none open now
Registered
3rd of 25
by date

Among the 25 studies in Colorectal Neoplasms by Merck & Co., Inc, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is one of 9 in phase 2, and was the 3rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 25 studies in Colorectal Neoplasms by Merck & Co., Inc is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Colorectal Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker. Participants with colorectal cancer, non-small-cell lung cancer, head and neck cancer, or esophageal cancer will be included.

03

Conditions studied

  • Colorectal Neoplasm
  • Head and Neck Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Esophageal Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years of age.
  • Participants must have colorectal cancer (CRC), recurrent or metastatic head \& neck (H\&N) or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer (NSCLC).
  • Participants must have a tumor sample or a blood sample tested positive for the presence of the biomarker.
  • Participants may have up to 3 prior regimens for CRC, up to 3 prior regimens for NSCLC, up to 2 prior regimens for H\&N and esophageal cancer.
  • Participants must have at least one .
  • Participants must have an (ECOG) performance status of 0, 1, or 2.
  • Participants must have adequate hematologic, renal, and liver functions.
  • Participants must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened.
  • Participants of must agree to use a medically accepted method of .

Exclusion criteria

Exclusion Criteria:

  • Participants who have received treatment for a second within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening.
  • Participants with unstable or progressing central nervous system (CNS) . Participants with known may be included if a) the subject is asymptomatic, b) there is no requirement for or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema.
  • Participants who received prior temozolomide or dacarbazine treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Temozolomide

    Drug: Temozolomide

Interventions

  • Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.

    Also known as: Temodal, TMZ, SCH 52365

06

What researchers measure

Primary outcomes

  1. Tumor Responses (Complete and Partial Response)

    Tumor response rate was based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    Time frame: From start of treatment until participant's disease progression, intolerable toxicity or death, which ever comes first

07

Results

Posted Jul 5, 2010
Limitations and caveats
Due to low response rate for colorectal cancer in interim analyses, low enrollment in head \& neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated.

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide
Started86
Completed0
Not completed86
Withdrew: Adverse event11
Withdrew: Progression of disease being studied69
Withdrew: Withdrawal by subject1
Withdrew: Non-compliance with protocol1
Withdrew: Administrative4

Outcome measures

PrimaryTumor Responses (Complete and Partial Response)

Tumor response rate was based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Time frame:
From start of treatment until participant's disease progression, intolerable toxicity or death, which ever comes first
Reported as:
Number · Participants
Tumor Responses (Complete and Partial Response)
ParticipantsTemozolomide
Number of participants with Complete Response0
Number of participants with Partial Response5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide—37/86 (43%)83/86 (96.5%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventTemozolomide
DYSPNOEARespiratory, thoracic and mediastinal disorders5/86
ANAEMIABlood and lymphatic system disorders4/86
THROMBOCYTOPENIABlood and lymphatic system disorders4/86
ATRIAL FIBRILLATIONCardiac disorders3/86
VOMITINGGastrointestinal disorders3/86
PYREXIAGeneral disorders3/86
DEHYDRATIONMetabolism and nutrition disorders3/86
NEUTROPENIABlood and lymphatic system disorders2/86
ACUTE MYOCARDIAL INFARCTIONCardiac disorders2/86
VERTIGOEar and labyrinth disorders2/86
Most frequent other events
Showing 10 of 31
Most frequent other events
EventTemozolomide
NAUSEAGastrointestinal disorders45/86
FATIGUEGeneral disorders36/86
VOMITINGGastrointestinal disorders35/86
ANOREXIAMetabolism and nutrition disorders31/86
CONSTIPATIONGastrointestinal disorders22/86
DIARRHOEAGastrointestinal disorders21/86
THROMBOCYTOPENIABlood and lymphatic system disorders19/86
ANAEMIABlood and lymphatic system disorders17/86
WEIGHT DECREASEDInvestigations13/86
HEADACHENervous system disorders13/86

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temozolomide
Mean62.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide
Female29
Male57
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hochhauser D, Glynne-Jones R, Potter V, Gravalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26. PubMed 23443801 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2007 to primary completion in Jun 2009, 28 months.

Results were first posted in Jul 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2006
First posted
Jan 18, 2007
StartActual
Jan 26, 2007
Primary completionActual
Jun 11, 2009
CompletionActual
Jun 11, 2009
Results first posted
Jul 5, 2010
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423150
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Jan 26, 2007
Primary completion
Jun 11, 2009
Completion
Jun 11, 2009
Results posted
Jul 5, 2010
Last update
Jun 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion